Screener › Biotech Small Cap Aktien
Biotech Small Cap Aktien
Small und Micro Cap Biotech-Aktien unter 5 Mrd. USD Marktkapitalisierung — Hochrisiko, Hochrendite Pipeline-Plays in Gentherapie, Onkologie, seltenen Erkrankungen und Präzisionsmedizin.
| Ticker | Unternehmen | Kurs | Marktkapitalisierung | Kurspotenzial | 52W Pos. | Smart Money |
|---|---|---|---|---|---|---|
| INDV | Indivior Pharmaceuticals, Inc. | $39.99 +0.48% | $4.73B | 27.1% | 89.9% | — |
| VCYT | Veracyte, Inc. | $57.99 +1.6% | $4.63B | -12.8% | 92.4% | — |
| LIVN | LivaNova PLC | $84.03 +0.49% | $4.62B | -3.1% | 97.2% | — |
| WAY | Waystar Holding Corp. | $23.91 +1.92% | $4.59B | 40.2% | 27.5% | — |
| FOLD | Amicus Therapeutics | $14.49 +0% | $4.55B | 0.1% | 99.9% | — |
| VKTX | Viking Therapeutics | $38.71 +3.39% | $4.49B | 139.2% | 78% | — |
| NVST | Envista Holdings | $27.51 -0.43% | $4.48B | 7.9% | 75% | — |
| ACAD | Acadia Pharmaceuticals | $25.77 -0.77% | $4.41B | 25.3% | 70.2% | — |
| EWTX | Edgewise Therapeutics | $40.10 +1.37% | $4.31B | 22.2% | 87.9% | — |
| MMSI | Merit Medical Systems | $71.45 +0.51% | $4.26B | 25.3% | 31.6% | — |
| LFST | LifeStance Health Group, Inc. | $10.99 -2.48% | $4.2B | -4% | 92% | — |
| DOCS | Doximity, Inc. | $22.86 +4.6% | $4.18B | 6.6% | 9.6% | — |
| IRTC | iRhythm Technologies | $126.03 -0.36% | $4.14B | 42% | 22.7% | — |
| DNLI | Denali Therapeutics | $25.74 -0.35% | $4.09B | 31.8% | 92.5% | — |
| CON | Concentra Group Holdings Parent | $31.86 -0.16% | $4.08B | -1.1% | 96.5% | — |
| ICUI | ICU Medical, Inc. | $159.43 +2.88% | $3.98B | 8.2% | 97.8% | — |
| CPRX | Catalyst Pharmaceuticals, Inc. | $31.50 +0.16% | $3.86B | 0.5% | 92.2% | — |
| RCUS | Arcus Biosciences, Inc. | $29.99 -1.12% | $3.77B | 19.2% | 92.6% | — |
| FIE.DE | Fielmann | $43.75 -0.34% | $3.67B | 34.6% | 20.6% | — |
| BEAM | Beam Therapeutics | $35.32 +1.52% | $3.63B | 44.6% | 90.9% | — |
| OGN | Organon & Co. | $13.57 +0.18% | $3.56B | -17.1% | 99.7% | — |
| PRVA | Privia Health Group, Inc. | $27.19 -0.62% | $3.43B | 15.6% | 96.2% | — |
| HAE | Haemonetics Corporation | $75.04 -0.04% | $3.41B | 13.5% | 69.3% | — |
| NHC | National HealthCare Corporation | $217.40 -0.48% | $3.4B | — | 97.3% | — |
| OPCH | Option Care Health, Inc. | $21.36 -2.47% | $3.35B | 33.8% | 17.8% | — |
| ARQT | Arcutis Biotherapeutics | $26.07 +1.01% | $3.26B | 32.8% | 69.5% | — |
| SFZN.SW | Siegfried Holding | $73.90 +2.92% | $3.24B | 34.2% | 24.2% | — |
| ITGR | Integer Holdings Corporation | $93.51 -1.71% | $3.18B | 4.3% | 51.7% | — |
| CLDX | Celldex Therapeutics | $37.95 -1.09% | $2.98B | 51.6% | 93.8% | — |
| ACHC | Acadia Healthcare Company, Inc. | $31.09 -2.57% | $2.86B | -7.2% | 91.9% | — |
| SUPN | Supernus Pharmaceuticals, Inc. | $47.24 -1.69% | $2.74B | 33% | 56.1% | — |
| VIRP.PA | Virbac | $325.00 -2.11% | $2.72B | 27% | 31% | — |
| NKTR | Nektar Therapeutics | $73.15 +2.97% | $2.47B | 109.5% | 59.3% | — |
| XRAY | DENTSPLY SIRONA Inc. | $12.32 +5.75% | $2.47B | 8.8% | 37.9% | — |
| TMDX | TransMedics Group | $71.23 +3.44% | $2.46B | 64.7% | 11.6% | — |
| PGNY | Progyny, Inc. | $30.93 +2.35% | $2.42B | -2.7% | 99.1% | — |
| VCEL | Vericel Corporation | $46.56 -0.89% | $2.38B | 19.1% | 93.8% | — |
| LMAT | LeMaitre Vascular | $103.72 +0.82% | $2.37B | 14.5% | 63.4% | — |
| ASTH | Astrana Health Inc. | $46.91 -4.6% | $2.33B | 0.4% | 86% | — |
| PBH | Prestige Consumer Healthcare In | $48.86 -1.13% | $2.31B | 36.7% | 16.6% | — |
| DMP.DE | Dermapharm Holding | $46.55 -1.9% | $2.31B | 8.2% | 73.5% | — |
| MD | Pediatrix Medical Group, Inc. | $27.39 +2.35% | $2.25B | -15.4% | 99.9% | — |
| TECN.SW | Tecan Group | $175.90 -0.57% | $2.23B | -2.2% | 92.5% | — |
| AGIO | Agios Pharmaceuticals | $37.39 -0.51% | $2.22B | 9% | 63.8% | — |
| ZLAB | Zymeworks | $19.08 -0.21% | $2.15B | 74.6% | 12.4% | — |
| HRMY | Harmony Biosciences Holdings, I | $37.01 -0.67% | $2.14B | 21.3% | 74.9% | — |
| ADMA | ADMA Biologics | $9.16 +2.35% | $2.12B | 92.1% | 14.7% | — |
| OCUL | Ocular Therapeutix | $9.66 +0.21% | $2.12B | 180.4% | 33.6% | — |
| UFPT | UFP Technologies | $272.07 -0.11% | $2.1B | 19.3% | 93.3% | — |
| RXRX | Recursion Pharmaceuticals | $3.96 +4.21% | $2.1B | 67.8% | 27% | — |
| NEOG | Neogen Corporation | $9.51 +1.82% | $2.07B | 26.2% | 72.1% | — |
| OMCL | Omnicell | $45.24 +5.14% | $2.06B | 35.5% | 65.3% | — |
| SEM | Select Medical Holdings Corpora | $16.51 -0.12% | $2.05B | -0.1% | 91% | — |
| SRPT | Sarepta Therapeutics | $19.18 -0.52% | $2.02B | 14.7% | 58.8% | — |
| NVCR | NovoCure | $17.32 +0.7% | $2.01B | 50.1% | 82.4% | — |
| NEO | NeoGenomics, Inc. | $15.16 +0% | $1.97B | -0.3% | 96.2% | — |
| ADUS | Addus HomeCare Corporation | $105.73 +0.53% | $1.97B | 25.5% | 48.7% | — |
| ANIP | ANI Pharmaceuticals, Inc. | $85.05 -1.14% | $1.93B | 32.5% | 60.8% | — |
| IOVA | Iovance Biotherapeutics | $4.19 -2.78% | $1.87B | 110% | 63.5% | — |
| ANAB | AnaptysBio | $62.31 -1.75% | $1.84B | 39.8% | 83.5% | — |
| DVAX | Dynavax Technologies | $15.50 +0% | $1.82B | 3.2% | 50% | — |
| CMPS | COMPASS Pathways | $12.84 -5.73% | $1.73B | 73.9% | 78.9% | — |
| HCSG | Healthcare Services Group, Inc. | $24.62 -2.11% | $1.69B | 6.4% | 91.4% | — |
| VIR | Vir Biotechnology, Inc. | $10.02 -0.2% | $1.69B | 115.1% | 78.1% | — |
| FTRE | Fortrea Holdings Inc. | $17.85 +3.3% | $1.69B | -8.2% | 94.3% | — |
| INVA | Innoviva | $21.82 -2.2% | $1.61B | 62.7% | 61.4% | — |
| DRW3.DE | Draegerwerk | $84.90 -1.16% | $1.59B | 19.6% | 60.7% | — |
| NVAX | Novavax | $9.35 -4% | $1.54B | 50.9% | 54.6% | — |
| PRGO | Perrigo Company plc | $11.09 +0.64% | $1.53B | 48.8% | 9.7% | — |
| PSNL | Personalis | $14.34 +5.29% | $1.5B | -24.3% | 95.5% | — |
| ENOV | Enovis Corporation | $25.90 +15.11% | $1.49B | 63.3% | 38.2% | — |
| ATEC | Alphatec Holdings | $9.33 +4.6% | $1.43B | 79.3% | 15.2% | — |
| INSP | Inspire Medical Systems, Inc. | $49.45 +5.32% | $1.42B | 4.7% | 9.7% | — |
| FAE.MC | Faes Farma | $4.56 -1.51% | $1.42B | 18.3% | 34.3% | — |
| IART | Integra LifeSciences Holdings C | $18.18 +0.72% | $1.41B | -4.1% | 92.8% | — |
| AHCO | AdaptHealth Corp. | $10.27 -4.55% | $1.4B | 36.3% | 35.8% | — |
| AMN | AMN Healthcare Services Inc | $35.77 +2.94% | $1.39B | -16.5% | 97.7% | — |
| PAHC | Phibro Animal Health Corporatio | $34.13 +2.62% | $1.38B | 33.6% | 24.8% | — |
| STAA | STAAR Surgical Company | $27.34 -1.62% | $1.36B | 8.5% | 57.9% | — |
| BLFS | BioLife Solutions, Inc. | $27.79 -1.14% | $1.36B | 15.6% | 81.8% | — |
| MNKD | MannKind Corporation | $4.27 -5.53% | $1.32B | 77.8% | 47.7% | — |
| ARDX | Ardelyx | $5.34 +1.33% | $1.32B | 205.2% | 29.2% | — |
| CRVS | Corvus Pharmaceuticals | $15.17 -0.39% | $1.28B | 119.7% | 49.1% | — |
| SDGR | Schrodinger | $17.00 +0.71% | $1.27B | 22.8% | 47.3% | — |
| QDEL | QuidelOrtho Corporation | $18.00 -1.37% | $1.23B | 4.9% | 31.5% | — |
| COLL | Collegium Pharmaceutical, Inc. | $37.47 +1.19% | $1.22B | 45% | 38.3% | — |
| AORT | Artivion, Inc. | $24.66 +2.88% | $1.2B | 70.3% | 18.9% | — |
| AZTA | Azenta, Inc. | $25.67 -0.66% | $1.18B | 2.1% | 37.8% | — |
| AVNS | Avanos Medical, Inc. | $24.92 -0.04% | $1.17B | — | 96.5% | — |
| OPK | OPKO Health | $1.50 -1.32% | $1.13B | 191.7% | 82.5% | — |
| USPH | US Physical Therapy | $73.38 +1.42% | $1.12B | 27.7% | 43% | — |
| CERT | Certara | $7.13 +2.3% | $1.11B | 4.9% | 28.4% | — |
| XNCR | Xencor | $14.89 -0.73% | $1.1B | 91.4% | 67.7% | — |
| CNMD | Conmed Corporation | $35.11 +3.78% | $1.06B | 12.8% | 14.6% | — |
| TNDM | Tandem Diabetes Care | $15.42 +0.65% | $1.06B | 87.3% | 27.7% | — |
| PCRX | Pacira BioSciences, Inc. | $25.59 +0.79% | $1.01B | 15.9% | 76.8% | — |
| EUZ.DE | Eckert and Ziegler | $15.85 -0.31% | $991.8M | 39.4% | 26.1% | — |
| CBAV.MC | Clinica Baviera | $58.40 -1.68% | $936M | — | 84.3% | — |
| EVT.DE | Evotec | $5.15 +0.19% | $914.6M | 33.4% | 30.1% | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $19.61 -0.15% | $864.7M | 12.2% | 20.3% | — |
| HSTM | HealthStream | $29.07 +2.32% | $849.3M | 10.1% | 94.5% | — |
| INMD | InMode | $14.60 -1.35% | $839.2M | -1.8% | 46.8% | — |
| CTKB | Cytek Biosciences, Inc. | $4.62 +0.65% | $596.6M | 23.1% | 49.5% | — |
| LBIRD.PA | Lumibird | $26.90 +4.67% | $593.6M | 9.7% | 93.7% | — |
| EDIT | Editas Medicine | $3.65 +0% | $560.1M | 58.3% | 69.2% | — |
| WEAV | Weave Communications | $6.70 +1.82% | $533.1M | 30.6% | 50.6% | — |
| PACB | Pacific Biosciences | $1.66 -1.19% | $515.6M | 48.1% | 34.8% | — |
| EOLS | Evolent Health | $6.99 +1.3% | $460.3M | 109.8% | 49.4% | — |
| CCCC | C4 Therapeutics | $4.14 -3.72% | $457.7M | 222.1% | 72.4% | — |
| PRLD | Prelude Therapeutics | $4.99 +1.63% | $397.4M | 60.3% | 85.8% | — |
| REG1V.HE | Revenio Group | $12.50 -0.32% | $363.6M | 55% | 2.8% | — |
| FATE | Fate Therapeutics | $2.99 +2.4% | $348.5M | 81% | 90.4% | — |
| FYB.DE | Formycon | $19.32 +1.05% | $341.4M | 105.3% | 22.7% | — |
| TMCI | Treace Medical Concepts | $4.56 +8.31% | $295.8M | -12.3% | 51.3% | — |
| SBS.DE | Stratec | $18.46 +1.43% | $224.4M | 37.6% | 12.9% | — |
| RNA | Avidity Biosciences | $13.01 -4.69% | $222.5M | 92.2% | 30% | — |
| EMBC | Embecta Corp | $3.28 -2.09% | $194.6M | 22% | 4% | — |
| CRBU | Caribou Biosciences | $1.83 +0.55% | $181.5M | 555.7% | 22.5% | — |
| HCAT | Health Catalyst | $2.29 +10.1% | $169.2M | -17% | 42.2% | — |
| AMWL | Amwell | $9.29 +0.43% | $155.2M | -19.3% | 89.3% | — |
| VXRT | Vaxart | $0.63 -0.87% | $152.4M | 376.6% | 63.7% | — |
| HYPR | Hyperfine | $1.27 -2.31% | $126.1M | 70.6% | 34.9% | — |
| SEER | Seer Bio | $2.19 +35.19% | $120.4M | 82.7% | 74.4% | — |
| NNOX | Nano-X Imaging | $1.32 +1.54% | $91.9M | 339.4% | 11.8% | — |
| TELA | Tela Bio | $0.79 +9% | $35.2M | 186.2% | 16.8% | — |
| CTSO | Cytosorbents Corporation | $0.43 +10.26% | $27M | 568.6% | 9.2% | — |
| MARI.VI | Marinomed Biotech | $9.45 -1.56% | $18.9M | 429.1% | 6.9% | — |
Analyse und Kontext
Dieser sektorbezogene Screener zeigt aktuell 127 Aktien aus dem ausgewählten Segment — täglich aktualisiert. Das durchschnittliche KGV liegt bei 39.1x. Das durchschnittliche Umsatzwachstum beträgt 19%. Sektoren durchlaufen zyklische Phasen die stark mit makroökonomischen Faktoren korrelieren — Zinsniveau, Wirtschaftswachstum, Rohstoffpreise und regulatorisches Umfeld beeinflussen die Branchendynamik entscheidend. Analysten sehen im Schnitt 55.6% Kurspotenzial in diesen Sektortiteln. Vergleiche die Kennzahlen dieser Aktien mit dem Branchendurchschnitt um relative Über- und Unterbewertungen zu identifizieren. Sektorkonzentration erhöht das Portfoliorisiko — achte auf ausreichende Diversifikation über verschiedene Branchen und Geschäftsmodelle.
Bereit zu investieren?
Vergleiche die besten Broker für deutsche und internationale Aktien — Gebühren, Plattformen und Angebote im Direktvergleich.
Broker vergleichen →